{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:13Z","timestamp":1777385293648,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The purpose of <jats:italic>ex vivo<\/jats:italic> drug screening in the context of precision oncology is to serve as a functional diagnostic method for therapy efficacy modeling directly on patient-derived tumor cells. Here, we report a case study using integrated multiomics <jats:italic>ex vivo<\/jats:italic> drug screening approach to assess therapy efficacy in a rare metastatic squamous cell carcinoma of the parotid gland. Tumor cells isolated from lymph node metastasis and distal subcutaneous metastasis were used for imaging-based single-cell resolution drug screening and reverse-phase protein array-based drug screening assays to inform the treatment strategy after standard therapeutic options had been exhausted. The drug targets discovered on the basis of the <jats:italic>ex vivo<\/jats:italic> measured drug efficacy were validated with histopathology, genomic profiling, and <jats:italic>in vitro<\/jats:italic> cell biology methods, and targeted treatments with durable clinical responses were achieved. These results demonstrate the use of serial <jats:italic>ex vivo<\/jats:italic> drug screening to inform adjuvant therapy options prior to and during treatment and highlight HER2 as a potential therapy target also in metastatic squamous cell carcinoma of the salivary glands.<\/jats:p>","DOI":"10.3389\/fonc.2021.735820","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T05:19:31Z","timestamp":1631769571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Ex Vivo Drug Screening Informed Targeted Therapy for Metastatic Parotid Squamous Cell Carcinoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Noora","family":"Nyk\u00e4nen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Arjonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ville","family":"H\u00e4rm\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Blaesius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismo","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teijo","family":"Kuopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha","family":"Kononen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha K.","family":"Rantala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2020.04.036","article-title":"Image-Based Ex Vivo Drug Screen to Assess Targeted Therapies in Recurrent Thymoma","volume":"145","author":"Arjonen","year":"2020","journal-title":"Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1186\/s12885-020-07092-w","article-title":"Ex Vivo Modelling of Drug Efficacy in a Rare Metastatic Urachal Carcinoma","volume":"20","author":"M\u00e4kel\u00e4","year":"2020","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.06.007","article-title":"Ex Vivo Assessment of Targeted Therapies in a Rare Metastatic Epithelial-Myoepithelial Carcinoma","volume":"22","author":"M\u00e4kel\u00e4","year":"2020","journal-title":"Neoplasia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.31487\/j.COR.2020.07.01","article-title":"Ex\u00a0Vivo Modelling of Therapy Efficacy for Rare Krugenberg Tumors \u2013 A Report of Two Cases","volume":"3","author":"Arjonen","year":"2020","journal-title":"Clin Oncol Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.016","article-title":"Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-Derived Cells","volume":"76","author":"Kettunen","year":"2019","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13791","article-title":"Clonal Evolution of MEK\/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case","volume":"39","author":"Lehtomaki","year":"2019","journal-title":"Anticancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening","volume":"73","author":"Tyner","year":"2013","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature14119","article-title":"Axitinib Effectively Inhibits BCR-ABL1(T315I) With a Distinct Binding Conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1703094114","article-title":"Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid-Derived Hematologic Malignancies","volume":"114","author":"Kurtz","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-018-0205-2","article-title":"Combined Chemosensitivity and Chromatin Profiling Prioritizes Drug Combinations in CLL","volume":"3","author":"Schmidl","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-Based Ex Vivo Drug Screening for Patients With Aggressive Haematological Malignancies: Interim Results From a Single-Arm, Open-Label, Pilot Study","volume":"12","author":"Snijder","year":"2017","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"6","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular Profiling of Cancer Patients Enables Personalized Combination Therapy: The I-PREDICT Study","volume":"5","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and Transcriptomic Profiling Expands Precision Cancer Medicine: The WINTHER Trial","volume":"5","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0380-z","article-title":"Utility of ctDNA to Support Patient Selection for Early Phase Clinical Trials: The TARGET Study","volume":"5","author":"Rothwell","year":"2019","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2602","article-title":"Novel Therapeutic Targets in Salivary Duct Carcinoma Uncovered by Comprehensive Molecular Profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted Therapy for Advanced Salivary Gland Carcinoma Based on Molecular Profiling: Results From MyPathway, a Phase IIa Multiple Basket Study","volume":"3","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3853","article-title":"Growth Rate Inhibition Metrics Correct for Confounders in Measuring Sensitivity to Cancer Drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-008-0074-1","article-title":"Comparative Cytokeratin Expression in the Different Cell Types of Salivary Gland Mucoepidermoid Carcinoma","volume":"4","author":"Azevedo","year":"2008","journal-title":"Head Neck Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"ZE04","DOI":"10.7860\/JCDR\/2015\/11289.5572","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2\/neu) in Salivary Gland Carcinomas: A Review of Literature","volume":"9","author":"Alotaibi","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.oraloncology.2017.06.023","article-title":"Combination of Docetaxel, Trastuzumab and Pertuzumab or Treatment With Trastuzumab-Emtansine for Metastatic Salivary Duct Carcinoma","volume":"72","author":"van Boxtel","year":"2017","journal-title":"Oral Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab Emtansine Versus Treatment of Physician\u2019s Choice in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results From a Randomised Open-Label Phase 3 Trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.432","article-title":"Lapatinib, A HER2 Tyrosine Kinase Inhibitor, Induces Stabilization and Accumulation of HER2 and Potentiates Trastuzumab-Dependent Cell Cytotoxicity","volume":"28","author":"Scaltriti","year":"2009","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1905","article-title":"Reduced Dose and Intermittent Treatment With Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2\/neu-Overexpressing Breast Tumor Xenografts","volume":"17","author":"Rimawi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4314","article-title":"Lapatinib Enhances Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity via Upregulation of HER2 in Malignant Mesothelioma Cells","volume":"34","author":"Okita","year":"2015","journal-title":"Oncol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou\u2013Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3407","article-title":"Clinical Benefit of Lapatinib-Based Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated P95her2 Receptor","volume":"16","author":"Scaltriti","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.8027","article-title":"Multicenter Phase II Study of Eoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006","volume":"31","author":"Rimawi","year":"2013","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0286-T","article-title":"Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue","volume":"15","author":"Snowden","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","article-title":"Is CD47 an Innate Immune Checkpoint for Tumor Evasion","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04784-0","article-title":"Development and Characterization of CD54-Targeted immunoPET Imaging in Solid Tumors","volume":"47","author":"Wei","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15500","article-title":"CD73 Acts as a Prognostic Biomarker and Promotes Progression and Immune Escape in Pancreatic Cancer","volume":"24","author":"Chen","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers12010092","article-title":"Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing","volume":"12","author":"Tuomainen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2017.09.008","article-title":"Salivary Duct Carcinoma: An Aggressive Salivary Gland Malignancy With Opportunities for Targeted Therapy","volume":"74","author":"Schmitt","year":"2017","journal-title":"Oral Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment Relevant Target Immunophenotyping of 139 Salivary Gland Carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1080\/0284186X.2020.1730005","article-title":"Treatment Outcomes of Patients With Salivary Duct Carcinoma Undergoing Surgery and Postoperative Radiotherapy","volume":"59","author":"Lee","year":"2020","journal-title":"Acta Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-Trastuzumab Emtansine (T-DM1) in Patients With HER2-Amplified Tumors Excluding Breast and Gastric\/Gastroesophageal Junction (GEJ) Adenocarcinomas: Results From the NCI-MATCH Trial (EAY131) Subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1086\/341943","article-title":"A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer","volume":"71","author":"Vahteristo","year":"2002","journal-title":"Am J Hum Genet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"R20","DOI":"10.1186\/bcr2832","article-title":"Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 Mutations in High-Risk Finnish BRCA1\/2-Founder Mutation-Negative Breast and\/or Ovarian Cancer Individuals","volume":"13","author":"Kuusisto","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/2159-8290.CD-19-0966","article-title":"Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer","volume":"10","author":"Smyth","year":"2020","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-Generation Characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2017.05.005","article-title":"Characterization, Treatment and Outcomes of Salivary Ductal Carcinoma Using the National Cancer Database","volume":"71","author":"Osborn","year":"2017","journal-title":"Oral Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.735820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T05:19:36Z","timestamp":1631769576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.735820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":42,"alternative-id":["10.3389\/fonc.2021.735820"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.735820","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"article-number":"735820"}}